MediciNova's ibudilast misses in Phase II for methamphetamine dependence

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported on March 29 that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat methamphetamine dependence.

The trial enrolled about 140 patients seeking treatment for methamphetamine

Read the full 405 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE